These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 26966615)

  • 1. Criteria for Drug Reimbursement Decision-Making: An Emerging Public Health Challenge in Bulgaria.
    Iskrov G; Stefanov R
    Balkan Med J; 2016 Jan; 33(1):27-35. PubMed ID: 26966615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insight into reimbursement decision-making criteria in Bulgaria: implications for orphan drugs.
    Iskrov GG; Raycheva RD; Stefanov RS
    Folia Med (Plovdiv); 2013; 55(3-4):80-6. PubMed ID: 24712287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges to orphan drugs access in Eastern Europe: the case of Bulgaria.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Health Policy; 2012 Nov; 108(1):10-8. PubMed ID: 22939047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eliciting societal preferences of reimbursement decision criteria for anti cancer drugs in South Korea.
    Kwon SH; Park SK; Byun JH; Lee EK
    Expert Rev Pharmacoecon Outcomes Res; 2017 Aug; 17(4):411-419. PubMed ID: 28019130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-Criteria Decision Analysis for Assessment and Appraisal of Orphan Drugs.
    Iskrov G; Miteva-Katrandzhieva T; Stefanov R
    Front Public Health; 2016; 4():214. PubMed ID: 27747207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European drug reimbursement systems' legitimacy: five-country comparison and policy tool.
    Cleemput I; Franken M; Koopmanschap M; le Polain M
    Int J Technol Assess Health Care; 2012 Oct; 28(4):358-66. PubMed ID: 22980497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reimbursement decisions in health policy--extending our understanding of the elements of decision-making.
    Wirtz V; Cribb A; Barber N
    Health Policy; 2005 Sep; 73(3):330-8. PubMed ID: 16039351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of economic evidence in Canadian oncology reimbursement decision-making: to lambda and beyond.
    Rocchi A; Menon D; Verma S; Miller E
    Value Health; 2008; 11(4):771-83. PubMed ID: 18179658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk management frameworks for human health and environmental risks.
    Jardine C; Hrudey S; Shortreed J; Craig L; Krewski D; Furgal C; McColl S
    J Toxicol Environ Health B Crit Rev; 2003; 6(6):569-720. PubMed ID: 14698953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
    Sullivan SD; Mauskopf JA; Augustovski F; Jaime Caro J; Lee KM; Minchin M; Orlewska E; Penna P; Rodriguez Barrios JM; Shau WY
    Value Health; 2014; 17(1):5-14. PubMed ID: 24438712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stated and Revealed Preferences for Funding New High-Cost Cancer Drugs: A Critical Review of the Evidence from Patients, the Public and Payers.
    MacLeod TE; Harris AH; Mahal A
    Patient; 2016 Jun; 9(3):201-22. PubMed ID: 26370257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative study of the role of disease severity in drug reimbursement decision making in four European countries.
    Franken M; Stolk E; Scharringhausen T; de Boer A; Koopmanschap M
    Health Policy; 2015 Feb; 119(2):195-202. PubMed ID: 25456017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
    Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
    Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decision-making criteria for medicine reimbursement in Slovenia: an expert panel discussion.
    Detiček A; Janzic A; Locatelli I; Kos M
    BMC Health Serv Res; 2018 Jun; 18(1):496. PubMed ID: 29945634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries.
    Kamusheva M; Vassileva M; Savova A; Manova M; Petrova G
    Front Public Health; 2018; 6():61. PubMed ID: 29556491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A synthesis of drug reimbursement decision-making processes in organisation for economic co-operation and development countries.
    Barnieh L; Manns B; Harris A; Blom M; Donaldson C; Klarenbach S; Husereau D; Lorenzetti D; Clement F
    Value Health; 2014; 17(1):98-108. PubMed ID: 24438723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions-Report of the ISPOR Stated Preference Research Special Interest Group.
    Marsh K; van Til JA; Molsen-David E; Juhnke C; Hawken N; Oehrlein EM; Choi YC; Duenas A; Greiner W; Haas K; Hiligsmann M; Hockley KS; Ivlev I; Liu F; Ostermann J; Poder T; Poon JL; Muehlbacher A
    Value Health; 2020 Jul; 23(7):831-841. PubMed ID: 32762984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An Evidence Framework for Off-Patent Pharmaceutical Review for Health Technology Assessment in Emerging Markets.
    Brixner D; Kaló Z; Maniadakis N; Kim K; Wijaya K
    Value Health Reg Issues; 2018 Sep; 16():9-13. PubMed ID: 29605800
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.